Cyclacel Pharmaceuticals, Inc.

Dividend yield
9.32 %
$0.6 anually
P/E ratio
Payout ratio
Proportion of net income paid out as dividends to shareholders
Company profitability (EPS)
past 12 months
CASH payout ratio
Cyclacel Pharmaceuticals, Inc. last quarter cash income being paid in the form of dividends.
Last quarter
Become our supporter to unlock all data!
Stock volatility (Beta)
See how volatile CYCCP stock is compared to other dividend stocks and to its sector
past 12 months
Become our supporter to unlock all data!
Company debt level
How much debt Cyclacel Pharmaceuticals, Inc. have in comparison to other dividend stocks
Become our supporter to unlock all data!
Cyclacel Pharmaceuticals, Inc. description

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Company profile
Market cap
Nano (31.30M)
Company CEO
Spiro Rombotis
Price history Cyclacel Pharmaceuticals, Inc.
Loading price stock history...
CYCCP dividends payouts
Similar stocks as Cyclacel Pharmaceuticals, Inc.